Search

Your search keyword '"Nomura, Masashi"' showing total 5 results
Start Over Author "Nomura, Masashi" Journal bmc urology
5 results on '"Nomura, Masashi"'

4. Chronic expanding hematoma in the retroperitoneal space: a case report

Author

Kazuhiro Suzuki, Takahiro Syuto, Nomura Masashi, Yoshitaka Sekine, and Motoaki Hatori

Subjects
Male, medicine.medical_specialty, Soft Tissue Neoplasm, Urology, Treatment outcome, Case Report, Hydronephrosis, Diagnosis, Differential, Hematoma, Humans, Medicine, Retroperitoneal space, Retroperitoneal Space, Aged, business.industry, Retroperitoneal, General Medicine, medicine.disease, Surgery, Radiography, Left ureter, Treatment Outcome, Chronic disease, medicine.anatomical_structure, Reproductive Medicine, Chronic Disease, Radiology, Differential diagnosis, business
Abstract

Background Chronic expanding hematoma is a rare condition that develops after surgery, trauma, or injury. It can also develop at any location in the body in the absence of trauma. Clinical findings and various diagnostic imaging modalities can aid in the differential diagnosis of this condition. In general, hematomas are naturally reabsorbed and rarely cause serious problems. However, hematomas that develop slowly without a history of trauma, surgery, or bleeding disorders could be difficult to differentiate from soft tissue neoplasms. In the present case, we describe a patient, without any history or physical evidence of trauma, who exhibited a large chronic expanding hematoma in the retroperitoneal space that resulted in hydronephrosis because of the pressure exerted on the left ureter. Case presentation A 69-year-old man presented to our hospital with a swollen lesion in the left flank. A mass, 19 cm in diameter, was detected in the retroperitoneal space by computed tomography. We suspected the presence of a chronic expanding hematoma, soft tissue tumor, or left renal artery aneurysm. Surgical treatment was performed. However, postoperative histopathological examination indicated that the mass was a nonmalignant chronic expanding hematoma. No recurrence was observed during a 2-year follow-up period. Conclusion In patients without a history of trauma who present slowly growing masses, the differential diagnosis should include chronic expanding hematoma in addition to cysts and soft tissue tumors. Moreover, the use of magnetic resonance imaging and computed tomography is essential to differentiate between chronic expanding hematoma and soft tissue tumors.

Published
2013
Full Text
View/download PDF

5. A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients.

Author

Yoshiyuki Miyazawa, Yoshitaka Sekine, Takahiro Syuto, Masashi Nomura, Hidekazu Koike, Hiroshi Matsui, Yasuhiro Shibata, Kazuto Ito, Kazuhiro Suzuki, Miyazawa, Yoshiyuki, Sekine, Yoshitaka, Syuto, Takahiro, Nomura, Masashi, Koike, Hidekazu, Matsui, Hiroshi, Shibata, Yasuhiro, Ito, Kazuto, and Suzuki, Kazuhiro

Subjects
GONADOTROPIN releasing hormone, PROSTATE cancer, ADRENAL diseases, ANDROGENS, TESTOSTERONE, STANOLONE, DEHYDROEPIANDROSTERONE, LUTEINIZING hormone releasing hormone antagonists, OLIGOPEPTIDES, ADRENAL glands, PROSTATE tumors, TESTIS, THERAPEUTICS
Abstract

Background: Adrenal androgens play an important role in the development of castration-resistant prostate cancer therapeutics. The effect of gonadotropin-releasing hormone (GnRH) antagonists on adrenal androgens has not been studied sufficiently. We measured testicular and adrenal androgen levels in patients treated with a GnRH antagonist.Methods: This study included 47 patients with histologically proven prostate cancer. All of the patients were treated with the GnRH antagonist degarelix. The mean patient age was 73.6 years. Pre-treatment blood samples were collected from all of the patients, and post-treatment samples were taken at 1, 3, 6, and 12 months after starting treatment. Testosterone (T), dihydrotestosterone (DHT), dehydroepiandrosterone (DHEA), 17β-estradiol (E2), and androstenedione (A-dione) were measured by liquid chromatography-mass spectrometry. Dehydroepiandrosterone-sulfate (DHEA-S), luteinizing hormone, and follicle-stimulating hormone levels were measured by electro-chemiluminescence immunoassays.Results: A significant reduction in T level (97.3% reduction) was observed in the patients 1 month after initiating treatment. In addition, levels of DHT, E2, DHEA-S, and A-dione decreased 1 month after initiating treatment (93.3, 84.9, 16.8, and 35.9% reduction, respectively). T, DHT, E2, DHEA-S, and A-dione levels remained significantly suppressed (97.1, 94.6, 85.3, 23.9, and 40.5% reduction, respectively) 12 months after initiating treatment. A significant decrease in DHEA level (15.4% reduction) was observed 12 months after initiating treatment.Conclusions: Serum adrenal androgen levels decreased significantly in patients treated with a GnRH antagonist. Thus, long-term GnRH antagonist treatment may reduce serum adrenal androgen levels. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results